GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer

Cheng,Lifang; Gou,Lanying; Wei,Ting; Zhang,Jian

doi:10.3892/ijo.2020.5086

GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer

Authors:
- Lifang Cheng
- Lanying Gou
- Ting Wei
- Jian Zhang
View Affiliations

Affiliations: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China
Published online on: June 22, 2020 https://doi.org/10.3892/ijo.2020.5086
Pages: 858-870

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI), is widely applied as a first‑line treatment for non‑small cell lung cancer (NSCLC) and greatly improves the clinical outcomes of patients. However, acquired resistance to EGFR‑TKIs remains a major clinical challenge. Here, we identified guanylate‑binding protein‑1 (GBP1) as a novel protein related to erlotinib resistance, and explored the specific mechanism by which GBP1 is involved in erlotinib resistance. First, the human NSCLC cells PC9ER and HCC827ER were generated by exposing cells to increasing concentrations of erlotinib over 6 months. We screened different genes between erlotinib‑sensitive and erlotinib‑resistant cells with data from the Gene Expression Omnibus database and detected the expression of these genes in erlotinib‑resistant and erlotinib‑sensitive cells by quantitative real‑time polymerase chain reaction (qPCR). Moreover, we constructed GBP1‑knockdown and GBP1‑overexpressing cells to determine the IC50 value of erlotinib, to perform an apoptosis assay and to examine cell cycle distribution. A subcutaneous tumorigenesis test was used to analyze how GBP1 affects erlotinib resistance. Then, mass spectrometry analysis and coimmunoprecipitation were performed to verify the interaction between GBP1 and phosphoglycerate kinase 1 (PGK1). Changes in epithelial‑mesenchymal transition (EMT)‑related markers were observed following the upregulation and downregulation of PGK1 expression. Finally, a rescue experiment was used to determine whether GBP1 regulates EMT through PGK1. In the present study, GBP1 was significantly upregulated in erlotinib‑resistant cells, compared with erlotinib‑sensitive cells. In vitro and in vivo experiments showed that upregulated GBP1 expression contributed to erlotinib resistance, while decreased GBP1 expression had the opposite effect. As shown by performing survival analysis, high GBP1 expression predicted poor prognosis in patients with lung adenocarcinoma. Furthermore, the interaction between GBP1 and PGK1 was confirmed, and a rescue experiment revealed that GBP1 regulates EMT via PGK1. Finally, functional experiments showed that EMT is involved in erlotinib resistance. Our study suggests that GBP1 regulates erlotinib resistance via PGK1‑mediated EMT signaling, suggesting GBP1 as a potential therapeutic target in erlotinib‑resistant NSCLC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, et al: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 30:2063–2069. 2012. View Article : Google Scholar : PubMed/NCBI
3	Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
4	Suda K, Rivard CJ, Mitsudomi T and Hirsch FR: Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Rev Anticancer Ther. 17:779–786. 2017. View Article : Google Scholar : PubMed/NCBI
5	Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29(suppl_1): i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
6	Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner RS, Vieth M, Waldner M, Steinberg P, Hohenadl C, et al: GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis. 34:153–162. 2013. View Article : Google Scholar
7	Yu CJ, Chang KP, Chang YJ, Hsu CW, Liang Y, Yu JS, Chi LM, Chang YS and Wu CC: Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J Proteome Res. 10:3778–3788. 2011. View Article : Google Scholar : PubMed/NCBI
8	Yamakita I, Mimae T, Tsutani Y, Miyata Y, Ito A and Okada M: Guanylate binding protein 1 (GBP-1) promotes cell motility and invasiveness of lung adenocarcinoma. Biochem Biophys Res Commun. 518:266–272. 2019. View Article : Google Scholar : PubMed/NCBI
9	Tipton AR, Nyabuto GO, Trendel JA, Mazur TM, Wilson JP, Wadi S, Justinger JS, Moore GL, Nguyen PT and Vestal DJ: Guanylate-binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel. Biochem Biophys Res Commun. 478:1617–1623. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ji X, Zhu H, Dai X, Xi Y, Sheng Y, Gao C, Liu H, Xue Y, Liu J, Shi J, et al: Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme. Cancer Biomark. 25:275–290. 2019. View Article : Google Scholar
11	Quintero M, Adamoski D, Reis LMD, Ascenção CFR, Oliveira KRS, Gonçalves KA, Dias MM, Carazzolle MF and Dias SMG: Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC Cancer. 17:7272017. View Article : Google Scholar : PubMed/NCBI
12	Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J, Li Z, Chen B, Zhang X, Pan H, et al: MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer Res. 77:5782–5794. 2017. View Article : Google Scholar : PubMed/NCBI
13	Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, et al: RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 6:63772015. View Article : Google Scholar : PubMed/NCBI
14	Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel Rahman M, Wang X, Levine AD, Rho JK, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
15	Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, et al: Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Sci Rep. 5:130762015. View Article : Google Scholar
16	Smyth GK: Limma: linear models for microarray. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey VJ, Huber W, Irizarry RA and Dudoit S: Springer; New York, NY: pp. 397–420. 2005, View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 366:701–704. 1993. View Article : Google Scholar : PubMed/NCBI
19	Massagué J: G1 cell-cycle control and cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Geng YH, Wang P, Zhou YT, Yang H, Huo YF, Zhang HQ, Li Y, He HY, Tian XX, et al: Extracellular ATP promotes breast cancer invasion and epithelial-mesenchymal transition via hypoxia-inducible factor 2α signaling. Cancer Sci. 110:2456–2470. 2019.PubMed/NCBI
21	Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
22	Oser MG, Niederst MJ, Sequist LV and Engelman JA: Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin. Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
23	Thomas H: Colorectal cancer: CRC endothelial regulation. Nat Rev Gastro Hepat. 13:6822016. View Article : Google Scholar
24	Wadi S, Tipton AR, Trendel JA, Khuder SA and Vestal DJ: hGBP-1 expression predicts shorter progression-free survival in ovarian cancers, while contributing to paclitaxel resistance. J Cancer Ther. 7:994–1007. 2016. View Article : Google Scholar
25	Duan Z, Foster R, Brakora KA, Yusuf RZ and Seiden MV: GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol. 57:25–33. 2006. View Article : Google Scholar
26	Zhou JW, Tang JJ, Sun W and Wang H: PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adeno-carcinoma. Mol Med. 25:112019. View Article : Google Scholar
27	Schneider CC, Archid R, Fischer N, Bühler S, Venturelli S, Berger A, Burkard M, Kirschniak A, Bachmann R, Königsrainer A, et al: Metabolic alteration–Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics. Int J Surg. 22:92–98. 2015. View Article : Google Scholar : PubMed/NCBI
28	Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, Jiang Y, Wu H, Jiang Y, Lu X, et al: Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. Br J Cancer. 112:1332–1339. 2015. View Article : Google Scholar : PubMed/NCBI
29	Fu D, He C, Wei J, Zhang Z, Luo Y, Tan H and Ren C: PGK1 is a potential survival biomarker and invasion promoter by regulating the HIF-1alpha-mediated epithelial-mesenchymal transition process in breast cancer. Cell Physiol Biochem. 51:2434–2444. 2018. View Article : Google Scholar
30	Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 19:279–290. 2013. View Article : Google Scholar
31	Lou W, Chen Y, Zhu KY, Deng H, Wu T and Wang J: Polyphyllin I overcomes EMT-associated resistance to erlotinib in lung cancer cells IL-6/STAT3 pathway inhibition. Biol Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI
32	Jakobsen KR, Demuth C, Sorensen BS and Nielsen AL: The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
33	Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al: Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 38:455–468. 2019. View Article : Google Scholar